|
Showing 1 - 25 of
151 matches in All Departments
'A brilliant book packed with powerful insights from the world's
most successful investors' Tony Robbins 'A profound, eloquent, and
much-needed call for a reassessment of how we build our portfolios
and live our lives' Stig Brodersen 'A classic ... for generations,
will define what it means to be a better investor and a better
human' Guy Spier Billionaire investors. If we think of them, it's
with a mixture of awe and suspicion. Clearly, they possess a kind
of genius - the proverbial Midas Touch. But are the skills they
possess transferable? And would we really want to be them? Do they
have anything to teach us besides making money? In Richer, Wiser,
Happier, award-winning journalist William Green has spent nearly
twenty-five years interviewing these investing wizards and
discovered that their talents expand well beyond the financial
realm and into practical philosophy. Green ushers us into the lives
of more than forty of the world's super-investors, visiting them in
their offices, vacation homes, and even their places of worship -
all to share what they have to teach us. Green brings together the
thinking of some of the best investors, from Warren Buffett to
Howard Marks to John Templeton, and provides gems of insight that
will enrich you not only financially but also professionally and
personally.
In the memorable words of Ragnar Frisch, econometrics is 'a
unification of the theoretical-quantitative and the
empirical-quantitative approach to economic problems'. Beginning to
take shape in the 1930s and 1940s, econometrics is now recognized
as a vital subdiscipline supported by a vast-and still rapidly
growing-body of literature. Following the positive reception of The
Rise of Econometrics (2013) (978-0-415-61678-2), Routledge now
announces a new collection bringing together the best that has been
published on the practical application and functional use of
economic metrics and measurements. With a comprehensive
introduction, newly written by the editor, which places the
assembled materials in their historical and intellectual context,
Applied Econometrics is an essential work of reference. This fully
indexed collection will be particularly useful as an indispensable
database allowing scattered and often fugitive material to be
easily located. It will also be welcomed as a crucial tool
permitting rapid access to less familiar-and sometimes
overlooked-texts. For researchers and students, as well as economic
policy-makers, it is a vital one-stop research and pedagogic
resource.
The story of Depo-Provera joins the national struggle over the
drug's FDA approval to the state legal issues raised by its
contraceptive and criminal justice uses. Depo-Provera is known as
an injectable hormonal birth control method, but few are familiar
with its dark and complicated history. Depo-Provera was tested on
women since the mid-1960s without their informed consent until it
was FDA-approved in 1992, but never FDA-approved as chemical
castration for male sex offenders. Contraceptive Risk is William
Green's landmark study of Depo-Provera. Based on a fascinating
combination of archival materials and interviews, the book is
framed as three interconnected stories told by Judith Weisz, who
chaired the FDA's Public Board of Inquiry on Depo-Provera, a
scientific court; by Anne MacMurdo who brought a products liability
suit against Upjohn, the drug's manufacturer, for the deleterious
side effects she suffered from the drug's use; and by Roger
Gauntlett, an Upjohn heir who, when he was convicted of sexual
assault, refused to take a dose of his family's own medicine as a
probation condition. Together these three stories of Depo-Provera's
convoluted fifty year odyssey call for a paradigm shift in
pharmaceutical drug development. Contraceptive Risk is a thoroughly
researched and engrossing approach to the scientific, political and
institutional forces involved in health law and policy, as well as
the multifaceted politics of measuring risk.
This volume is a collection of methodological developments and
applications of simulation-based methods that were presented at a
workshop at Louisiana State University in November, 2009. The first
two papers are extensions of the GHK simulator: one reconsiders the
computation of the probabilities in a discrete choice model while
another example uses an adaptive version of sparse-grids
integration (SGI) instead of simulation. Two studies are focused
specifically on the methodology: the first compares the performance
of the maximum-simulated likelihood (MSL) approach with a proposed
composite marginal likelihood (CML) approach in multivariate
ordered-response situations, while the second examines methods of
testing for the presence of heterogeneity in the heterogeneity
model. Further topics examined include: education savings accounts,
parent contributions and education attainment; estimating the
effect of exchange rate flexibility on financial account openness;
estimating a fractional response model with a count endogenous
regressor; and modelling and forecasting volatility in a bayesian
approach.
The story of Depo-Provera joins the national struggle over the
drug's FDA approval to the state legal issues raised by its
contraceptive and criminal justice uses. Depo-Provera is known as
an injectable hormonal birth control method, but few are familiar
with its dark and complicated history. Depo-Provera was tested on
women since the mid-1960s without their informed consent until it
was FDA-approved in 1992, but never FDA-approved as chemical
castration for male sex offenders. Contraceptive Risk is William
Green's landmark study of Depo-Provera. Based on a fascinating
combination of archival materials and interviews, the book is
framed as three interconnected stories told by Judith Weisz, who
chaired the FDA's Public Board of Inquiry on Depo-Provera, a
scientific court; by Anne MacMurdo who brought a products liability
suit against Upjohn, the drug's manufacturer, for the deleterious
side effects she suffered from the drug's use; and by Roger
Gauntlett, an Upjohn heir who, when he was convicted of sexual
assault, refused to take a dose of his family's own medicine as a
probation condition. Together these three stories of Depo-Provera's
convoluted fifty year odyssey call for a paradigm shift in
pharmaceutical drug development. Contraceptive Risk is a thoroughly
researched and engrossing approach to the scientific, political and
institutional forces involved in health law and policy, as well as
the multifaceted politics of measuring risk.
|
You may like...
Higher
Michael Buble
CD
(1)
R487
Discovery Miles 4 870
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|